peptide hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
In 1960, the United States developed its first Single Integrated Operational Plan, a range of targeting options, and described launch procedures and target sets against which nuclear weapons would be launched, variants of which were in use from 1961 to 2003. That year also saw the start of the Missile Defense Alarm System, an American system of 12 early-warning satellites that provided limited notice of Soviet intercontinental ballistic missile launches between 1960 and 1966. The Ballistic Missile Early Warning System was completed in 1964. The most powerful atomic bomb ever made, the Tsar Bomba, was tested by the Soviets on October 30, 1961. It was 50 megatons, or equal to 50 million tons of regular explosives. A complex and worrisome situation developed in 1962, in what is called the Cuban Missile Crisis. The Soviet Union placed medium-range ballistic missiles 90 miles (140 km) from the United States, possibly as a direct response to American Jupiter missiles placed in Turkey. After intense negotiations, the Soviets ended up removing the missiles from Cuba and decided to institute a massive weapons-building program of their own. In exchange, the United States dismantled its launch sites in Turkey, although this was done secretly and not publicly revealed for over two decades. First Secretary Nikita Khrushchev did not even reveal this part of the agreement when he came under fire by political opponents for mishandling the crisis.
IgE was simultaneously discovered in 1966–67 by two independent groups: Ishizaka's team at the Children's Asthma Research Institute and Hospital in Denver, USA, and by Gunnar Johansson and Hans Bennich in Uppsala, Sweden. Their joint paper was published in April 1969.
This nuclide was long thought to be stable, but in 2003 it was found to be unstable, with a very long half-life of 20.1 billion billion years; it is the last step in the chain before stable thallium-205. Because this bottleneck is so long-lived, very small quantities of the final decay product have been produced, and for most practical purposes bismuth-209 is the final decay product. In the past, during the first few million years of the history of the Solar System, there were more unstable high-mass nuclides in existence, and the four chains were longer, as they included nuclides that have since decayed away. Notably, 244Pu, 237Np, and 247Cm have half-lives over a million years and would have then been bottlenecks higher in the 4n, 4n+1, and 4n+3 chains respectively - 244Pu and 247Cm have been identified as having been present. (There is no nuclide with a half-life over a million years above 238U in the 4n+2 chain.) Today some of these formerly extinct isotopes are again in existence as they have been manufactured. Thus they again take their places in the chain: plutonium-239, used in nuclear weapons, is the major example, decaying to uranium-235 via alpha emission with a half-life 24,500 years. There has also been large-scale production of neptunium-237, resurrecting the extinct fourth chain. The tables below hence start the four decay chains at isotopes of californium with mass numbers from 249 to 252.
Sources: en.wikipedia.org
One of the most important events in the decade after the war was the creation of the Union of South Africa (later the Republic of South Africa). It proved a key ally to Britain as a Dominion of the British Empire during the World Wars. At the start of the First World War a crisis ensued when the South African government led by Louis Botha and other former Boer fighters, such as Jan Smuts, declared support for Britain and agreed to send troops to take over the German colony of German South-West Africa (Namibia). Many Boers were opposed to fighting for Britain, especially against Germany, which had been sympathetic to their struggle. Some bittereinders and their allies took part in a revolt known as the Maritz rebellion. The rebellion was quickly suppressed, and the leading Boer rebels escaped lightly (especially compared with leading Irish rebels of the Easter Rising), with imprisonment of 6-7 years and heavy fines. Two years later, they were released from prison, as Louis Botha recognised the value of reconciliation.
Explosive decompression of a hyperbaric environment can produce severe barotrauma, followed by severe decompression bubble formation and other related injury. The Byford Dolphin incident is an example. Rapid uncontrolled decompression from caissons, airlocks, pressurised aircraft, spacecraft, and pressure suits can have similar effects of decompression barotrauma. Collapse of a pressure resistant structure such as a submarine, submersible, or atmospheric diving suit can cause rapid compression barotrauma. A rapid change of altitude can cause barotrauma when internal air spaces cannot be equalised. Excessively strenuous efforts to equalise the ears using the Valsalva manoeuvre can overpressurise the middle ear, and can cause middle ear and/or inner ear barotrauma. An explosive blast and explosive decompression create a pressure wave that can induce barotrauma. Such trauma may occur as part of a broader blast injury pattern when the pressure wave affects gas-containing organs. The difference in pressure between internal organs and the outer surface of the body causes injuries to internal organs that contain gas, such as the lungs, gastrointestinal tract, and ear. Lung injuries can also occur during rapid decompression, although the risk of injury is lower than with explosive decompression. Mechanical ventilation can lead to barotrauma of the lungs. This can be due to either:
The same cannot be said for human bone collagen, as δ18O values in collagen seem to be impacted by drinking water, food water, and a combination of metabolic and physiological processes. δ18O values from bone minerals are essentially an averaged isotopic signature throughout the entire life of the individual. While carbon and nitrogen are used primarily to investigate the diets of ancient humans, oxygen isotopes offer insight into body water at different life stages. δ18O values are used to understand drinking behaviors, animal husbandry, and track mobility. 97 burials from the ancient Maya citadel of Tikal were studied using oxygen isotopes. Results from tooth enamel identified statistically different individuals, interpreted to be individuals from Maya lowlands, Guatemala, and potentially Mexico. Historical context combined with isotopic data from burials were used to argue that migrant individuals were a part of lower and higher social classes within Tikal. Female migrants who arrived in Tikal during Early Classic period could have been the brides of Maya elite.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.